PatternsRadar
Sign in

SANOFICONRSanofi Consumer Healthcare India Limited

NSE
Full chart
3,736.50INR-16.20 (-0.43%)Close · 6 Oct 2026
28 Jul 2026Last results
HealthcareSector
Pharmaceuticals & BiotechnologyIndustry
₹8,605 CrMarket cap
32.4P/E (TTM)
55.1%Delivery

Filings & corporate actions

9 results filed
CSV
Next results · Q2 FY27
Expected 28 Oct 2026 – 25 Nov 2026
Estimate: filed 28–56 days after quarter end, last 8 times
Dividend
₹75.00 per share · last 19 Jun 2026
2026
  • 28 JulresultsResults · Q1 FY27 · standalone+0.8%NSE
  • 21 JulshareholdingShareholding · 30 Jun 2026+1.1%NSE
  • 19 JundividendDividend · ₹75.00 per share-2.8%
  • 28 AprresultsResults · Q4 FY26 · standalone+2.3%NSE
  • 21 AprshareholdingShareholding · 31 Mar 2026-0.8%NSE
  • 25 FebresultsResults · Q3 FY26 · standalone+13.8%NSE
  • 14 JanshareholdingShareholding · 31 Dec 2025-0.8%NSE

Reaction to results · all yearsrose on day 0 in 6 of 9 CSV

QuarterFiledDay 0+5D+20DRel vol
Q1 FY2728 Jul 2026+0.8%-3.3%-11.7%9.8×
Q4 FY2628 Apr 2026+2.3%+1.7%-2.0%7.0×
Q3 FY2625 Feb 2026+13.8%+10.0%+7.2%239.4×
Q2 FY2612 Nov 2025+7.0%+1.9%-1.2%6.7×
Q1 FY264 Aug 2025+10.4%+7.1%+8.7%39.7×
Q4 FY2512 May 20250.0%+4.4%+2.8%0.2×
Q3 FY2521 Feb 2025-0.9%+0.5%+2.0%1.9×
Q2 FY2512 Nov 2024-1.1%-2.0%-1.3%2.6×
Q1 FY2518 Sept 2024+4.0%-0.8%-6.2%—
Average+4.0%+2.2%-0.2%

Close-to-close from the session before the filing could trade. Day 0 is the first session after it.

Growth · Q1 FY27

CSV
Revenue YoY+6.7%
Profit YoY+13.3%
Interest cost YoY-57.4%
Revenue QoQ+2.8%
Profit QoQ+1.5%
CAGR2Y3Y4Y5Y6Y7Y
Revenue——————
Profit——————

Key data

CSV
Open3,731.00
Day range3,704.00 – 3,764.40
52-week range3,691.00 – 5,255.00
From 52w high-28.9%
RSI (14)21.3
ATR (14)104.33
Volume3.4K
Avg volume (20D)6.9K
Rel volume0.50×
Volatility (1Y)30.1%
Turnover₹1.3Cr
SMA 50 / 2004,217.64 / 4,419.76

Delivery percentage

Latest · 6 Oct 202655.1%
20-day avg54.7%
1-year avg55.5%
Percentile (own history)38th
Range8.7–100.0%
Sessions511

Over the last 20 sessions SANOFICONR settled 54.7% of its traded quantity, which is above average for an NSE equity. That is in line with its own one-year average of 55.5%. The latest session ranks higher than 38% of the 511 sessions on record for it.

What delivery percentage measuresScan the whole market on delivery

IndustryPharmaceuticals
PeersDIVISLABLAURUSLABSSUNPHARMAWOCKPHARMADRREDDYMOREPENLAB

Performance returns

CSV
1D1W1M3M6M1Y
Price-0.43%-6.03%-11.15%-18.83%-18.38%-24.37%

Valuation

CSV
Market cap₹8,605 Cr
P/E (TTM)32.4
EPS (TTM)115.50
Shares outstanding2.30Cr
Listed13 Sept 2024

Ownership

CSV
Promoter71.27%
Promoter Δ QoQ0.00 pp
Public28.73%
FII2.60%
DII17.86%
Pledged0.00%

Quarterly results · standalone

CSV
Q2 FY26Q3 FY26Q4 FY26Q1 FY27
Revenue (₹ Cr)233.9251.0229.2235.7
YoY chg+46.3%+47.0%+32.8%+6.7%
Net profit (₹ Cr)62.966.567.868.8
YoY chg+39.8%+50.1%+35.6%+13.3%
Net margin26.9%26.5%29.6%29.2%
EPS27.3128.8729.4429.87

Shareholding over time

CSV

By quarter

30 Jun 2026 · promoter 71.27% · public 28.73%
6 Sept 2024: promoter 60.40%30 Sept 2024: promoter 60.40%10 Oct 2024: promoter 60.40%31 Dec 2024: promoter 60.40%31 Mar 2025: promoter 60.40%30 Jun 2025: promoter 71.27%30 Sept 2025: promoter 71.27%31 Dec 2025: promoter 71.27%31 Mar 2026: promoter 71.27%30 Jun 2026: promoter 71.27%
2024-092026-06
  • Promoter
  • Public and others
Promoter
71.27%
Public
28.73%
Promoter change
0.00 pp
Filed
21 Jul 2026
FII
2.60%
DII
17.86%
Promoter pledged
0.00%

Promoter and public shares of total equity, from the pattern filed each quarter. Institutional and pledge figures come from a separate filing stage whose backfill is still running, so they are absent for almost every instrument rather than zero.

Financials · quarterly statement

CSV
Standalone
₹ crore, as filed
 Q1 FY25Q2 FY25Q3 FY25AQ4 FY25Q1 FY26Q2 FY26Q3 FY26Q4 FY26Q1 FY27
Revenue from operations164.4159.9170.7172.6220.9233.9251.0229.2235.7
Other income0.84.25.05.25.63.04.65.66.3
Total income165.2164.1175.7177.8226.5236.9255.6234.8242.0
Total expenses102.0101.7110.0111.0154.2152.8165.1144.1150.1
└ Finance costs0.13.40.40.40.50.60.50.50.4
└ Depreciation1.11.51.02.03.03.33.43.23.3
Profit before tax38.961.262.866.878.984.190.590.791.9
Tax expense9.916.218.516.818.221.224.022.923.1
Net profit29.045.044.350.060.762.966.567.868.8
EPS12.5819.5419.2521.6926.3627.3128.8729.4429.87
Net margin17.64%28.14%25.95%28.97%27.48%26.89%26.49%29.58%29.19%
PBT margin23.66%38.27%36.79%38.70%35.72%35.96%36.06%39.57%38.99%
Tax rate25.45%26.47%29.46%25.15%23.07%25.21%26.52%25.25%25.14%

A audited · R restated by a later filing · negatives in parentheses. EPS and the share count are restated onto the same split-adjusted basis as the price chart, so they can be read against it; every rupee figure is exactly as filed. A quarterly filing carries a profit and loss only — there is no balance sheet behind it, and so no debt, cash flow or return-on-capital figure here. Latest filed 28 Jul 2026.

SANOFICONR at a glance

  • SANOFICONR closed at ₹3,736.5 on 6 Oct 2026, -0.43% on the day, -24.4% over one year, 28.9% below its 52-week high of ₹5,255.
  • Delivery was 55.1% of traded quantity on 6 Oct 2026, the 38th percentile of its own 511 sessions with a reading (20-session average 54.7%, 1-year average 55.5%).
  • Market capitalisation is ₹8,605 crore at a trailing P/E of 32.4 (trailing EPS ₹115.5).
  • Q1 FY27 results (standalone, filed 28 Jul 2026): revenue ₹236 crore (+6.7% year on year), net profit ₹69 crore (+13.3%); the price moved +0.8% on the first session after.
  • Promoters held 71.27% at 30 Jun 2026, unchanged on the previous filing.
  • Q2 FY27 results are expected between 28 Oct 2026 and 25 Nov 2026, going by past filing dates — an estimate, not an announcement.

About

CSV
Macro sectorHealthcare
Basic industryPharmaceuticals
ISININE0UOS01011
SeriesEQ
Listed13 Sept 2024
History from13 Sept 2024
Sessions511

Prices are adjusted for splits and bonuses. Delivery figures come from NSE’s daily reports and are unavailable for older sessions. Sourced from the eod2 dataset, last updated 6 Oct 2026.

More in Pharmaceuticals & Biotechnology

CSV

All Pharmaceuticals & Biotechnology stocks on the NSEAll Healthcare stocks on the NSE